Alnylam Pharma (ALNY) Tops Q1 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity
May 6, 2020 8:00 AM EDTAchieved First Quarter 2020 ONPATTRO® Net Product Revenues of $66.7 Million with More Than 950 Patients on Commercial Product Worldwide
Achieved First Quarter 2020 GIVLAARI® Net Product Revenues of $5.3 Million with More Than 50 Patients on Commercial Product in the U.S.
Completed New Drug Application and Filed Marketing Authorisation Application for Lumasiran, Advancing Another Alnylam Investigational RNAi Therapeutic toward Market
Announces New Positive Initial Topline Results from Ongoing Phase 1 Study of ALN-AGT in Hypertension with Over 90 Percent Knockdown of Angiotensinogen and an Over 10 mmHg Mean Reduction of 24-hour Systolic Blood Pressure Relative to Placebo... More
